Medivation Inc. and partner Astellas Pharma Inc. could win approval of their experimental prostate cancer drug within six months, after the companies on Monday filed a new drug application with the Food and Drug Administration.
The filing isn't unexpected, but it's a big step forward for San Francisco-based Medivation (NASDAQ: MDVN). Only two years ago, the company's experimental Alzheimer's disease drug Dimebon fizzled in a Phase III trial. But a nearly 1,200-patient, late-stage study of the prostate cancer drug -- called enzalutamide, or MDV-3100 -- showed strong results.
No comments:
Post a Comment